Latest MS research news

Latest MS research news | 10 June 2013

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trial

This analysis looked at 31 previous trials and extracted data on the treatment effects on MRI lesions and on relapse from each trial. They found that the effect of a treatment on relapses can be accurately predicted by the effect of that therapy on MRI lesions.

From MSIF

Latest MS research news | 10 June 2013

Assessing dalfampridine efficacy in the physician's office

This review article looks at dalfampridine, which has been shown to improve walking speed in people with MS. The trials which have taken place were based on consistency and not magnitude of response, therefore not making it applicable to physicians in a clinic setting. Alternatives were suggested.

From MSIF

Latest MS research news | 04 June 2013

Immunosuppressive therapy reduces axonal damage in progressive MS

This study from Sweden looked at biomarkers in the cerebrospinal fluid in people with progressive forms of MS and the impact of immunosuppressive therapy (mitoxantrone or rituximab) on these markers.

From MSIF

Latest MS research news | 04 June 2013

Neuro-ophthalmologic evaluation, quality of life, and functional disability in people with MS.

This study found that people with relapsing-remitting MS had a progressive decline in retinal nerve fibre layer thickness over time, indicating progressive axonal loss, with a lower quality of life and more functional disability.

From MSIF

Latest MS research news | 04 June 2013

Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients

This retrospective study looked at the efficacy and safety of mycophenolate mofetil (MMF), which is commonly used after organ transplantation to prevent graft rejection. The researchers found a positive effect of MMF on MS relapse and the treatment was quite well tolerated overall.

From MSIF

Latest MS research news | 28 May 2013

Predictive value of one month retinal nerve fiber layer thinning for deficits at six months after acute optic neuritis

The retinal nerve fibre layer (RNFL) was assessed in people with acute optic neuritis. The study group found a correlation between RNFL at 1 month and 6 months, suggesting that by 1 month, permanent injury has already occurred in the affected eyes.

From MSIF

Latest MS research news | 28 May 2013

T-cell response against varicella-zoster virus in people with MS treated with fingolimod

This study looked at the immune response against varicella-zoster virus (which causes chicken pox and shingles) and Epstein-Barr virus (which causes glandular fever) and found that a specific part of the immune response was reduced in people treated with fingolimod.

From MSIF

Latest MS research news | 28 May 2013

The effect of vitamin D-related interventions on MS relapses: a meta-analysis

This research group looked at five recently published studies to examine the effect of vitamin D supplementation on the relative risk of relapse in MS and found no association.

From MSIF

Latest MS research news | 21 May 2013

Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease

The researchers in this study looked at a specific imaging biomarker of spinal cord tissue injury called diffusion tensor imaging (DTI). This gives us an insight into the tract-specific substrates of physical impairment in MS and neuromyelitis optica (NMO).

From MSIF

Latest MS research news | 21 May 2013

Brain reserve and cognitive reserve in MS: What you've got and how you use it.

The results from this Italian study demonstrate that early life intellectual enrichment (cognitive reserve) protects people with MS from disease-related cognitive impairment independently of brain reserve.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial